Diabetic Peripheral Neuropathic Pain

Regular-release capsules

• Initial: 50 mg PO q8hr
• Maintenance: May increase to 100 mg PO q8hr within 1 week, as needed; not to exceed 300 mg/day

Extended-release tablets

• Initial: 165 mg PO qDay
• Maintenance: May increase to 330 mg PO qDay within 1 week based on response and tolerability; not to exceed 330 mg PO qDay
• See also Administration

Postherpetic Neuralgia

Regular-release capsules

• Initial: 150-300 mg/day PO divided q8-12hr
• Maintenance: May increase to 300 mg/day divided q8-12hr after 1 week, as needed

Extended-release tablets

• Initial: 165 mg PO qDay
• Maintenance: May increase to 330 mg PO qDay within 1 week based on response and tolerability; not to exceed 330 mg PO qDay
• Patients experiencing insufficient pain relief following 2-4 weeks of treatment with 330 mg PO qDay and tolerate the ER tablets, may be treated with up to 660 mg PO qDay